<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857905</url>
  </required_header>
  <id_info>
    <org_study_id>EK 1623/2020</org_study_id>
    <nct_id>NCT04857905</nct_id>
  </id_info>
  <brief_title>Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection</brief_title>
  <official_title>Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection - Evaluation of Neurosurgical Treatment Methods for Patients With Larger Brain Metastases - an Explorative Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background. Brain metastases (BM) are the most common intracranial tumor and occur in 20-40%&#xD;
      of all oncological patients. The most common primary cancer in brain metastases is lung&#xD;
      cancer, followed by melanoma, breast cancer, renal cancer and colorectal cancer. The&#xD;
      incidence of brain metastases has been increasing but the occurrence of brain metastases is&#xD;
      still associated with high morbidity and poor prognosis. The main treatment methods are&#xD;
      stereotactic radiosurgery (SRS), microsurgical resection and whole brain irradiation (WBRT).&#xD;
      In contrast to microsurgical resection, Gamma Knife radiosurgery (GKRS) is a non-invasive&#xD;
      neurosurgical method, which allows treatment in multimorbid patients with contraindications&#xD;
      for surgery in general anesthesia. Furthermore, stereotactic radiosurgery is the only local&#xD;
      treatment method for multiple disseminated and thereby non-resectable brain metastases. In&#xD;
      general, microsurgical resection is considered the treatment of choice for BM exceeding &gt;3 cm&#xD;
      in diameter. However, since the establishment of the dose-staged technique, larger metastases&#xD;
      can also be treated radiosurgically in selected patients. This novel method allows the&#xD;
      application of high cumulative dose for the treatment of complex brain metastases.&#xD;
&#xD;
      Aim. The aim of the study is to evaluate the clinical outcome in brain metastases patients&#xD;
      with tumor volume between 8 and 20 ccm3. The clinical outcome will be compared between&#xD;
      surgically and radiosurgically treated BM patients.&#xD;
&#xD;
      Patients and methods. The investigators plan to conduct an explorative prospective study&#xD;
      including about 50 radiosurgically and 50 surgically treated patients with brain metastases.&#xD;
      If a patient fulfill study-relevant inclusion criteria at the time of BM diagnosis, the&#xD;
      principle study investigator will offer both treatment options to the patient. Depending on&#xD;
      patient's choice, he/she will be categorized either to surgical or to radiosurgical treatment&#xD;
      group. For the outcome evaluation of the different treatment options, a comprehensive&#xD;
      database will be established. The study participations will not interfere with any clincally&#xD;
      indicated therapeutic decisions and the study participants will not be exposed to any&#xD;
      additional risks since both treatments represent suitable therapy options.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through completion of the study, an average of 1 year</time_frame>
    <description>Time from first treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tumor progression</measure>
    <time_frame>Through completion of the study, an average of half a year</time_frame>
    <description>Time from first treatment until local tumor progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Microsurgical Resection of larger Brain Metastasis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after counseling&#xD;
-&gt; Patients who after counseling decide for microsurgical resection of their brain metastasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiosurgery of larger Brain Metastasis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients over 18 years and under 90 years Patients with KPS ≥70 Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor Maximum of three brain metastases on the diagnostic MRI Tumor volume of 8-20 ccm3 on the diagnostic MRI Lobular brain metastases Patients without any contraindications for both treatment options Written, signed informed consent for study particaption after study counseling&#xD;
-&gt; Patients who after counseling decide for dose-staged radiosurgical treatment of their brain metastasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microsurgical resection</intervention_name>
    <description>Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.</description>
    <arm_group_label>Microsurgical Resection of larger Brain Metastasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gamma Knife radiosurgery</intervention_name>
    <description>Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.</description>
    <arm_group_label>Radiosurgery of larger Brain Metastasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years and under 90 years&#xD;
&#xD;
          -  Patients with KPS ≥70&#xD;
&#xD;
          -  Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor&#xD;
&#xD;
          -  Maximum of three brain metastases on the diagnostic MRI&#xD;
&#xD;
          -  Tumor volume of 8-20 ccm3 on the diagnostic MRI&#xD;
&#xD;
          -  Lobular brain metastases&#xD;
&#xD;
          -  Patients without any contraindications for both treatment options&#xD;
&#xD;
          -  Written, signed informed consent for study particaption after study explanation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years and over 90 years&#xD;
&#xD;
          -  Patients with KPS &lt;70&#xD;
&#xD;
          -  Patients with other primary tumor&#xD;
&#xD;
          -  More than three brain metastases on the diagnostic MRI&#xD;
&#xD;
          -  Tumor volume &lt;8 or &gt;20 ccm3 on the diagnostic MRI&#xD;
&#xD;
          -  Patients with contraindications for both treatment options&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josa Frischer, MD, PhD</last_name>
    <phone>+43 1 40400 45510</phone>
    <email>josa.frischer@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Cho, MD</last_name>
    <phone>+43 1 40400 45510</phone>
    <email>anna.cho@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurosurgery, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josa M Frischer, MD, PhD</last_name>
      <phone>004314040045510</phone>
      <email>josa.frischer@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Anna Cho, MD</last_name>
      <phone>004314040045510</phone>
      <email>anna.cho@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Dorfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl Rössler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Kiesel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Josa M Frischer, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gamma Knife Radiosurgery</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>Microsurgical resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

